Project Grant R01HL181110
Award Date 8/1/26
Completion Date 4/30/31
Dollars Obligated $843K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $169,348 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research applying partitioned polygenic risk scoring and machine learning-derived imaging phenotypes to discover novel mechanisms of cardiometabolic disease in people of South Asian ancestry. Dr. Bhattacharya will develop unbiased SNP-level and gene...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, for whole genome sequence interpretation to identify new genes and mechanisms underlying coronary artery disease and familial hypercholesterolemia. The award funds research to improve genetic diagnostic yield for familial hypercholesterolemia, an inherited form of...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $3,330,084 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, for a project grant investigating causal links between the maternal plasma proteome, preeclampsia, and future cardiovascular disease. The research leverages proteomic analysis of circulating microparticles isolated from maternal plasma samples collected across first, second, and...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $249,000 on March 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genomic and functional molecular analyses investigating the mechanistic links between clonal hematopoiesis of indeterminate potential (CHIP) and coronary artery disease (CAD). The recipient will discover further germline genetic predisposition that induces CHIP-related cardiovascular disease using an...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $185,196 on January 7, 2027 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a pilot multi-center cohort study examining patient and caregiver burden in chronic limb-threatening ischemia (CLTI). Aim 1 will assess how caregiver support relates to patient outcomes including quality of life, amputation, readmission, and mortality, collecting...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $170,432 under Project Grant K08HL183784 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). Dr. Urbut will develop and validate a novel Bayesian multivariate model integrating time-varying genetic and clinical factors across over 300 diagnostic phenotypes to identify latent disease signatures for genomic discovery and produce...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...